Basilea shareholders approve all proposals of the board of directors at the annual general meeting

    Basilea shareholders approve all proposals of the board of directors at the annual general meeting

Allschwil, Switzerland, April 24, 2024

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported that shareholders approved all proposals of the board of directors at today’s annual general meeting (AGM) for the financial year 2023.

At the AGM, the shareholders approved the annual report, the financial statements and the consolidated financial statements for the financial year 2023. They also endorsed carrying forward the accumulated deficit and approved the discharge of the members of the board of directors and the management committee.

Mr. Domenico Scala was re-elected as chairman and Mr. Leonard Kruimer, Dr. Martin Nicklasson, Dr. Nicole Onetto, Dr. Carole Sable and Dr. Thomas Werner were re-elected as members of the board of directors. In addition, Dr. Nicklasson, Dr. Onetto and Dr. Werner were re-elected to the compensation committee. The term of all board members lasts until the AGM 2025.

The shareholders also approved the proposed maximum aggregate amount of compensation for the board of directors for the period from the AGM 2024 to the AGM 2025, and the maximum aggregate amount of total compensation (fixed and variable) for the management committee for the financial year 2025. In a non-binding advisory vote, the shareholders endorsed the compensation report for the financial year 2023.

Finally, the shareholders re-elected Dr. Caroline Cron as independent proxy until the end of the next AGM and re-elected PricewaterhouseCoopers Ltd, Basel, as auditors for the financial year 2024.

At the AGM, 35.9% of the share capital, equivalent to 59.7% of the shares entitled to vote, was represented. In total, 69.9% of the share capital is currently registered in Basilea’s share register.

About Basilea

Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

Peer Nils Schröder, PhD Head of Corporate Communications & Investor Relations Basilea Pharmaceutica International Ltd, Allschwil Hegenheimermattweg 167b 4123 Allschwil Switzerland
Phone	[phone]
E-mail	[e-mail] [e-mail]

This press release can be downloaded from www.basilea.com.

Press release (PDF)